


#9/a
DmJ
3-13-03

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on 20 February 2003.

RECEIVED

MAR 04 2003

TECH CENTER 1600/2900



Printed: Carolyn C. Caires

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Findell and Marinkovich	Assignees:	FibroGen, Inc. and The Board of Trustees of The Leland Stanford Junior University
Title:	METHODS OF AFFECTING LAMININ 5 PROCESSING		
U.S. Serial No.:	09/854,188	Filing Date:	11 May 2001
Examiner:	R. M. DeBerry	Group Art Unit:	1647

Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the Restriction Requirement dated 20 September 2002, the period for response being extended until 20 February 2003 by the accompanying petition and fee, please consider the above-identified application in view of the following amendments and remarks.

IN THE CLAIMS

Please replace claims 4 and 7 with the following rewritten claims:

a1 4. A method of treating a condition characterized by neoplastic epithelial cells, the method comprising administering to a subject in need an effective amount of an agent that affects processing of laminin 5 by a BMP-1 related protein.

a2 7. The method of claim 6, wherein the squamous cell carcinoma is selected from the group consisting of skin cancer, lung cancer, head cancer, neck cancer, oral cancer, cervical cancer, tongue